We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Improving Metabolism With HDL Cholesterol

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00395148
First Posted: November 2, 2006
Last Update Posted: May 10, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Baker Heart Research Institute
Information provided by:
Bayside Health
  Purpose
High levels of good cholesterol (HDL) in our blood decreases our chance of having a heart attack. This relates in part to the role good cholesterol plays in reducing build up of fat in the arteries. However, good cholesterol has many other protective effects. We have recently identified three enzymes (proteins) activated by HDL in cells lining the blood vessels, which may be responsible for some of HDL's protective actions.

Condition Intervention
Heart Disease Diabetes Drug: rHDL

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Novel Mechanism Mediating Anti-atherosclerotic and Metabolic Actions of HDL Cholesterol

Resource links provided by NLM:


Further study details as provided by Bayside Health:

Primary Outcome Measures:
  • Metabolic parameters

Enrollment: 13
Study Start Date: March 2006
Study Completion Date: March 2008
Primary Completion Date: March 2008 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Aged 18 - 65 years
  • Free of overt coronary disease
  • Body mass index <35 kg.m-2
  • Fasting plasma glucose > 7 mmol/L-1
  • No major illness

Exclusion Criteria:

  • Unable to give informed consent
  • Smokers
  • Abnormal LFT, U&E, FBE or creatinine
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00395148


Locations
Australia, Victoria
Alfred Hospital
Melbourne, Victoria, Australia, 3004
Sponsors and Collaborators
Bayside Health
Baker Heart Research Institute
Investigators
Principal Investigator: Bronwyn A Kingwell, PhD Baker Heart Research Institute
  More Information

Publications:

Responsible Party: Prof Bronwyn Kingwell, Baker IDI Heart & Diabetes Institute
ClinicalTrials.gov Identifier: NCT00395148     History of Changes
Other Study ID Numbers: 175/04
First Submitted: October 31, 2006
First Posted: November 2, 2006
Last Update Posted: May 10, 2011
Last Verified: October 2006

Additional relevant MeSH terms:
Heart Diseases
Cardiovascular Diseases